Toppublicaties

Mammacarcinoom

Geselecteerd door: Mammacarcinoom
Dr. Willemien Menke-van der Houven van Oordt

Abemaciclib verkleint risico op recidief bij hoogrisico vroegstadium borstkanker
  • december 2022

Abemaciclib plus endocrine therapy for hormone receptor[1]positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

  • Stephen R D Johnston, Masakazu Toi, Joyce O’Shaughnessy, et al.
  • november 2022

Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.

  • Del Mastro L, Poggio F, Blondeaux E, et al.
  • oktober 2022

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.

  • Geyer CE Jr, Garber JE, Gelber RD, et al.
  • oktober 2022

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

  • Francois-Clement Bidard, Virginia G Kaklamani, Patrick Neven, et al.
  • september 2022

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.

  • Bidard FC, Hardy-Bessard AC, Dalenc F, et al.
  • september 2022

Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.

  • Jens Huober, Carlos H Barrios, Naoki Niikura, et al.
  • september 2022

Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial

  • Sonja B Vliek, Iris Noordhoek, Elma Meershoek-Klein Kranenbarg, et al.
  • augustus 2022

Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.

  • Rugo HS, Bardia A, Marmé F, et al.
  • augustus 2022

nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer

  • Erika Hamilton, Javier Cortes, Ozgur Ozyilkan, et al.
  • augustus 2022

Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression

  • Hans Wildiers, Thomas Meyskens, Sandrine Marréaud, et al.
  • augustus 2022

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response.

  • Loibl S, Schneeweiss A, Huober J, et al.
Dr. Willemien Menke-van der Houven van Oordt

Abemaciclib verkleint risico op recidief bij hoogrisico vroegstadium borstkanker
  • augustus 2022

Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial

  • Miguel Martin, Roberto Hegg, Sung-Bae Kim, et al.
Gedownload van https://medischeoncologie.nl/ op 22-03-2023 om 12:58. Copyright (C) 2023 BPM Medica.

Deel deze pagina